AbbVie Inc. $ABBV Shares Sold by BDF Gestion

BDF Gestion lessened its position in AbbVie Inc. (NYSE:ABBV) by 17.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,522 shares of the company’s stock after selling 7,178 shares during the quarter. AbbVie makes up 0.9% of BDF Gestion’s investment portfolio, making the stock its 19th largest holding. BDF Gestion’s holdings in AbbVie were worth $7,993,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie during the second quarter worth about $25,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the 2nd quarter worth approximately $26,000. TD Capital Management LLC lifted its holdings in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new position in AbbVie in the 2nd quarter valued at approximately $28,000. Finally, Financial Gravity Companies Inc. purchased a new position in AbbVie in the 2nd quarter valued at approximately $36,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ABBV. Wells Fargo & Company increased their price objective on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Citigroup reduced their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Bank of America boosted their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Price Performance

Shares of NYSE ABBV opened at $227.44 on Friday. The stock’s 50-day simple moving average is $226.63 and its 200-day simple moving average is $211.14. The firm has a market capitalization of $401.98 billion, a PE ratio of 172.30, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the firm posted $3.00 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.